-
Mashup Score: 0TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial - PubMed - 2 year(s) ago
ClinicalTrials.gov Identifier: NCT01327846.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy - 3 year(s) ago
Background:Beta-adrenergic antagonists or blockers (BB) are a cornerstone of cardiac therapy for multiple indications. However, BB are considered relatively contraindicated in amyloid cardiomyopathy due to poor tolerance. This intolerance is hypothesized to be due to concomitant neuropathy and significant restrictive cardiomyopathy. This study analyzes the incidence and characteristics of BB…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @CampbellMDPhD: 🚨Beta-blocker Tolerance in Amyloid Cardiomyopathy💔 Now published @FrontCVMedicine! https://t.co/XhPd9o3NUJ Excellent wo…
-
🚨Beta-blocker Tolerance in Amyloid Cardiomyopathy💔 Now published @FrontCVMedicine! https://t.co/XhPd9o3NUJ Excellent work from OSU Comprehensive #Amyloidosis Clinic led by @OSUWexMed med students @stuart_ramsell & Carlos Arias-Bermudez! #cardioonc #cardiotwitter #MedTwitter https://t.co/ZKMocBNVLR
-
-
Mashup Score: 1Washington University School of Medicine - 3 year(s) ago
Officially endorsed by the International Society of Cardio Oncology. Officially endorsed by the Heart Failure Society of America. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.This conference will be offered as a Live Webinar only (Based on Central Standard Time Zone) 7:45am Zoom opens for…
Source: cme.wustl.eduCategories: Cardiologists, Latest HeadlinesTweet-
Enjoy this special issue? Join us for the @WUSTLmed 2022 #Amyloidosis LIVE CME Webinar this Saturday, March 12th! Keynotes - Dr. Wechalekar @UCL - Dr. Ahmad @NMCardioVasc Multidisciplinary care ⚕️ Session for patients/family/caregivers Register https://t.co/2DnAxklENS https://t.co/4BeUMWgkxL https://t.co/b5vYHXXW0U
-
-
Mashup Score: 2
Amyloidosis is a heterogeneous disease that can be challenging to diagnose, frequently eluding even the most astute clinicians. Whether the clinical presentation is primarily cardiac, neurological, gastrointestinal, or renal in nature, symptoms are generally nonspecific and frequently attributed to more common causes of disease without consideration of amyloidosis. The multi-system nature of…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
🚨 Special Issue 🚨 Proceedings from @WUSTLmed's "Amyloidosis: A Hidden Disease with a Bright 💡 Future" in @amjmed, led by Dr. Katie Zhang & Dr. Dan Lenihan: https://t.co/2Y722WRi9s 10 papers on #amyloidosis multidisciplinary care! #MedTwitter #Cardioonc #CardioTwitter 🧵/11 https://t.co/VFQJeJmJoT
-
-
Mashup Score: 0When to suspect and how to approach a diagnosis of amyloidosis - 3 year(s) ago
Diagnoses of amyloidosis, particularly transthyretin amyloid cardiomyopathy (ATTR-CM), are steadily increasing throughout the world but the condition remains underdiagnosed. Patients with amyloidosis may present to a range of medical and surgical specialties, often with multi-system disease, and a high index of clinical suspicion is required for diagnosis. Bone scintigraphy and cardiovascular…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
To begin: "When to suspect and how to approach a diagnosis of #amyloidosis" by Drs. Steven Law & Julian Gillmore @UCL -Red Flags🚩 -Non-invasive investigation🔬 -Cardiac❤️evaluation -When to biopsy https://t.co/P4JkABjCBC 2/11 https://t.co/p8DNHg8BL0
-
-
Mashup Score: 0Management of Cardiac Symptoms in Amyloidosis - 3 year(s) ago
Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrythmias, conduction disturbances, and profound autonomic dysfunction. These symptoms present unique management challenges as compared to patients without CA and can be very debilitating. Thus, management of the cardiovascular symptoms of these patients plays a central role in their care. This review presents…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
"Management of Cardiac ❤️ Symptoms in #Amyloidosis" by Drs. Philip King @wustlcardfellow & Andy Kates @akates1 -Heart failure💔 -Atrial Fibrillation⚡️ -Ventricular arrhythmias💞 -Pacemakers & Devices -Orthostatic Hypotension -Aortic Stenosis https://t.co/uBoX6uA4EX 3/11 https://t.co/5268y1nat1
-
-
Mashup Score: 0Neuromuscular complications of systemic amyloidosis - 3 year(s) ago
Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues, frequently at a distance from the site of synthesis. The two most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy. Diagnosis can be challenging, and abundant suspicion is required to identify patients. As…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
"Neuromuscular 🧠🦵Complications of Systemic #Amyloidosis" by Drs. Dina Namiranian & Stefanie Geisler @WashUNeurology -Neuropathy types: autonomic, sensorimotor, others -Frequent hATTR misdiagnoses 😬 -Neuropathy diagnostics & findings 🔬 https://t.co/NnVIOmnqe4 4/11 https://t.co/mwIrzlqJ1y
-
-
Mashup Score: 0
Amyloidosis is a heterogeneous disease that can cause a wide array of non-specific symptoms when involving the gastrointestinal (GI) tract including weight loss, early satiety, change in bowel habits with diarrhea, constipation or alternating bowel pattern. Endoscopy with biopsy for Congo red staining establishes the diagnosis and fibril subtyping helps to guide targeted treatment options. Light…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
"Evaluation & Management Strategies for GI Involvement with #Amyloidosis" by Drs. Cassandra Fritz @cfritzMD & Elizabeth Blaney @EJBlaney @WUSTLmed -GI presentation 🤢 -Endoscopic diagnosis 🔎 -Gastroparesis, diarrhea, constipation💩 management https://t.co/HZzOMNgoTC 5/11 https://t.co/wnTEjyUdiv
-
-
Mashup Score: 0What Do The Elevated Protein Levels Mean In My Patients With Myeloma, Amyloidosis, and Related Disorders? - 3 year(s) ago
Multiple myeloma, light-chain (AL) amyloidosis and other plasma cell dyscrasias are characterized, in part, by abnormal production of paraproteins that are often responsible for the sequelae of those diseases. These paraproteins are whole or fragmented immunoglobulins produced by clonal antibody-secreting cells (usually plasma cells but occasionally B lymphocytes). Significant heterogeneity…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
"What do the Elevated Protein Levels Mean in my Patient with Myeloma🦴, #Amyloidosis, & Related Disorders? by Drs. Scott Goldsmith @ScottG_MD & Keith Stockerl-Goldstein @CyclingDoctor -Protein Electrophoresis -Immunotyping -Free light chains ⛓️ https://t.co/wpLRibp0SF 6/11 https://t.co/VWvn1X7R5F
-
-
Mashup Score: 0Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation - 3 year(s) ago
The management of immunoglobulin light chain (AL) amyloidosis is complex. Emerging data has shown promising results for several novel agents. We review the management of AL amyloidosis including factors that determine transplant eligibility, treatment options for transplant ineligible patients, and treatment options for relapsed/refractory AL amyloidosis. For carefully selected patients, high…
Source: The American Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
"Update on Current Therapy in Conjunction with Stem Cell Transplant 🩸 for Light Chain #Amyloidosis" by Drs. Maya Abdallah @MayaAbdallah_MD & Vaishali Sanchorawala @vsanchorawala @BU_Amyloidosis -Transplant & med regimens💊 -Relapsed AL options https://t.co/C5evaFQJl5 7/11 https://t.co/tfRni84Vay
-
https://t.co/2ojgBtUA4B Link between TET2 CHIP & response to Canakinumab